Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Real Time Quote from BATS)

$20.00 USD

20.00
329,573

+0.09 (0.45%)

Updated Aug 16, 2024 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Is Catalyst Pharmaceuticals (CPRX) Stock a Solid Choice Right Now?

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up

by Zacks Equity Research

Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst's (CPRX) third-quarter 2023 earnings are expected to have been driven by the robust performances of its two marketed drugs, Firdapse and Fycompa CIII.

Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

by Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

by Zacks Equity Research

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Insulet (PODD) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.

GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.

Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

Elevance Health (ELV) Beats Q3 Earnings, Hikes '23 Profit View

by Zacks Equity Research

Elevance Health's (ELV) Q3 results gain on growing medical customer base and strong pharmacy product revenues. Adjusted net income is currently projected to be more than $33.00 per share for 2023.

Tirthankar Chakraborty headshot

3 Solid Stocks to Buy for Superb Earnings Acceleration

by Tirthankar Chakraborty

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse

by Zacks Equity Research

The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Best Momentum Stocks to Buy for October 11th

by Zacks Equity Research

PBF, PRAX and CPRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 11, 2023.

New Strong Buy Stocks for October 11th

by Zacks Equity Research

PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.

Humana (HUM) Boosts Healthcare Choices for MA Members in Denver

by Zacks Equity Research

Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.